The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Vaccine adjuvants: Current state and future trends
Abstract
The problem with pure recombinant or synthetic antigens used in modern day vaccines is that they are generally far less immunogenic than older style live or killed whole organism vaccines. This has created a major need for improved and more powerful adjuvants for use in these vaccines. With few exceptions, alum remains the sole adjuvant approved for human use in the majority of countries worldwide. Although alum is able to induce a good antibody (Th2) response, it has little capacity to stimulate cellular (Th1) immune responses which are so important for protection against many pathogens. In addition, alum has the potential to cause severe local and systemic side‐effects including sterile abscesses, eosinophilia and myofascitis, although fortunately most of the more serious side‐effects are relatively rare. There is also community concern regarding the possible role of aluminium in neurodegenerative diseases such as Alzheimer's disease. Consequently, there is a major unmet need for safer and more effective adjuvants suitable for human use. In particular, there is demand for safe and non‐toxic adjuvants able to stimulate cellular (Th1) immunity. Other needs in light of new vaccine technologies are adjuvants suitable for use with mucosally‐delivered vaccines, DNA vaccines, cancer and autoimmunity vaccines. Each of these areas are highly specialized with their own unique needs in respect of suitable adjuvant technology. This paper reviews the state of the art in the adjuvant field, explores future directions of adjuvant development and finally examines some of the impediments and barriers to development and registration of new human adjuvants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives
Ellouz, F., Adam, A., Ciorbaru, R., & Lederer, E. (1974) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(74)90458-6 · Cited by 1,019
Nanoparticle Uptake by the Rat Gastrointestinal Mucosa: Quantitation and Particle Size Dependency
Jani, P., Halbert, G. W., Langridge, J., & Florence, A. T. (1990) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1990.tb07033.x · Cited by 920
The mucosal immune system: from fundamental concepts to vaccine development
McGhee, J. R., Mestecky, J., Dertzbaugh, M. T., Eldridge, J. H., Hirasawa, M., & Kiyono, H. (1992) · Vaccine · doi:10.1016/0264-410x(92)90021-b · Cited by 903
Handbook of Mucosal Immunology
(1994) · Elsevier eBooks · doi:10.1016/c2009-1-03796-4 · Cited by 706
Eldridge, J. H., Hammond, C. J., Meulbroek, J. A., Staas, J. K., Gilley, R. M., & Tice, T. R. (1990) · Journal of Controlled Release · doi:10.1016/0168-3659(90)90133-e · Cited by 689
Liposomes as immunological adjuvants
ALLISON, A. C., & GREGORIADIS, G. (1974) · Nature · doi:10.1038/252252a0 · Cited by 675
Kensil, C. R., Patel, U., Lennick, M., & Marciani, D. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.146.2.431 · Cited by 654
Adjuvants for human vaccines—current status, problems and future prospects
Gupta, R. K., & Siber, G. R. (1995) · Vaccine · doi:10.1016/0264-410x(95)00011-o · Cited by 551
Epithelial M Cells: Gateways for Mucosal Infection and Immunization
Neutra, M. R., Frey, A., & Kraehenbuhl, J.-P. (1996) · Cell · doi:10.1016/s0092-8674(00)80106-3 · Cited by 544
Heufler, C., Koch, F., & Schuler, G. (1988) · The Journal of experimental medicine · doi:10.1084/jem.167.2.700 · Cited by 540
Weiner, G. J., Liu, H.-M., Wooldridge, J. E., Dahle, C. E., & Krieg, A. M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.20.10833 · Cited by 519
Xiang, Z., & Ertl, H. C. J. (1995) · Immunity · doi:10.1016/s1074-7613(95)80001-8 · Cited by 477
ANTIGEN SAMPLING ACROSS EPITHELIAL BARRIERS AND INDUCTION OF MUCOSAL IMMUNE RESPONSES
Neutra, M. R., Pringault, E., & Kraehenbuhl, J.-P. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.275 · Cited by 474
Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs
Takahashi, H., Takeshfta, T., Morein, B., Putney, S., Germain, R. N., & Berzofsky, J. A. (1990) · Nature · doi:10.1038/344873a0 · Cited by 473
Vaccine design : the subunit and adjuvant approach
Powell, M. F., Newman, M. J., & Burdman, J. R. (1995) · Plenum Press eBooks · Cited by 451
Frey, A., Giannasca, K. T., Weltzin, R., Giannasca, P. J., Reggio, H., Lencer, W. I., & Neutra, M. R. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.3.1045 · Cited by 401
Biodegradable microspheres as a vaccine delivery system
Eldridge, J. H., Staas, J. K., Meulbroek, J. A., McGhee, J. R., Tice, T. R., & Gilley, R. M. (1991) · Molecular Immunology · doi:10.1016/0161-5890(91)90076-v · Cited by 399
Immunological notes. XVII–XXIV
Glenny, A. T., Pope, C. G., Waddington, H., & Wallace, U. (1926) · The Journal of Pathology and Bacteriology · doi:10.1002/path.1700290106 · Cited by 399
Eldridge, J. H., Staas, J. K., Meulbroek, J. A., Tice, T. R., & Gilley, R. M. (1991) · Infection and Immunity · doi:10.1128/iai.59.9.2978-2986.1991 · Cited by 368
Tyrrell, D. A., Heath, T. D., COLLEY, C. M., & Ryman, B. E. (1976) · Biochimica et Biophysica Acta (BBA) - Reviews on Biomembranes · doi:10.1016/0304-4157(76)90002-2 · Cited by 367
STUDIES ON THE O ANTIGEN OF SALMONELLA TYPHOSA
Johnson, A. G., Gaines, S., & Landy, M. (1956) · The Journal of Experimental Medicine · doi:10.1084/jem.103.2.225 · Cited by 358
Saponins as vaccine adjuvants.
Kensil, C. R. (1996) · PubMed · Cited by 350
Disis, M. L., Grabstein, K. H., Sleath, P. R., & Cheever, M. A. (1999) · PubMed · Cited by 340
Adjuvant Properties of Aluminum and Calcium Compounds
Gupta, R. K., Rost, B. E., Relyveld, E., & Siber, G. R. (1995) · Pharmaceutical Biotechnology · doi:10.1007/978-1-4615-1823-5_8 · Cited by 330
Sensitization and Antibody Formation after Injection of Tubercle Bacilli and Paraffin Oil.
Freund, J., Casals, J., & Hosmer, E. P. (1937) · Experimental Biology and Medicine · doi:10.3181/00379727-37-9625 · Cited by 311
Douce, G., Turcotte, C., Cropley, I., Roberts, M., Pizza, M., Domenghini, M., Rappuoli, R., & Dougan, G. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.5.1644 · Cited by 278
Structure, Distribution, and Origin of M Cells in Peyer’s Patches of Mouse Ileum
BYE, W. A., ALLAN, C. H., & TRIER, J. S. (1984) · Gastroenterology · doi:10.1016/s0016-5085(24)05125-4 · Cited by 274
Protection Against Vaginal SIV Transmission with Microencapsulated Vaccine
Marx, P. A., Compans, R. W., Gettie, A., Staas, J. K., Gilley, R. M., Mulligan, M. J., Yamshchikov, G. V., Chen, D., & Eldridge, J. H. (1993) · Science · doi:10.1126/science.8493576 · Cited by 261
New strategies for using mucosal vaccination to achieve more effective immunization
Walker, R. I. (1994) · Vaccine · doi:10.1016/0264-410x(94)90112-0 · Cited by 257
Edelman, R. (1980) · Clinical Infectious Diseases · doi:10.1093/clinids/2.3.370 · Cited by 245
Brewer, J. M., Conacher, M., Satoskar, A., Bluethmann, H., & Alexander, J. (1996) · European Journal of Immunology · doi:10.1002/eji.1830260915 · Cited by 232
A Compendium of Vaccine Adjuvants and Excipients
Vogel, F. R., & Powell, M. F. (1995) · Pharmaceutical Biotechnology · doi:10.1007/978-1-4615-1823-5_7 · Cited by 217
Adjuvants: current status, clinical perspectives and future prospects
Audibert, F. M., & Lise, L. D. (1993) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(93)90204-w · Cited by 214
Adjuvants: current status, clinical perspectives and future prospects
Audibert, F. M., & Lise, L. D. (1993) · Immunology Today · doi:10.1016/0167-5699(93)90046-n · Cited by 194
Distinctive adjuvanticity of synthetic analogs of mycobacterial water-soluble components
Audibert, F., CHEDID, L. A., Lefrancier, P., et al. (1976) · Cellular Immunology · doi:10.1016/0008-8749(76)90053-8 · Cited by 154
Tsuji, T., Hamajima, K., Fukushima, J., Xin, K.-Q., Ishii, N., Aoki, I., Ishigatsubo, Y., Tani, K., Kawamoto, S., Nitta, Y., et al. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.8.4008 · Cited by 152
Structural and Immunological Characterization of the Vaccine Adjuvant QS-21
Kensil, C. R., Wu, J., & Soltysik, S. (1995) · Pharmaceutical biotechnology · doi:10.1007/978-1-4615-1823-5_22 · Cited by 139
Marinaro, M., Boyaka, P. N., Finkelman, F. D., Kiyono, H., Jackson, R. J., Jirillo, E., & McGhee, J. R. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.3.415 · Cited by 126
Inulin‐derived adjuvants efficiently promote both Th1 and Th2 immune responses
Silva, D. G., Cooper, P. D., & Petrovsky, N. (2004) · Immunology and Cell Biology · doi:10.1111/j.1440-1711.2004.01290.x · Cited by 120
Self-citationThe theory and practical application of adjuvants
Stewart-Tull, D. E. S. (1995) · Cited by 119
Estevez, F., Carr, A., Solórzano, L., Valiente, O. G., Mesa, C., Barroso, O., Sierra, G. V. G., & Fernandez, L. E. (1999) · Vaccine · doi:10.1016/s0264-410x(99)00219-4 · Cited by 114
The biological activities of mannans and related complex carbohydrates.
Tizard, I. R., Carpenter, R. H., McAnalley, B. H., et al. (1989) · PubMed · Cited by 106
Selection of potent immunological adjuvants for vaccine construction
McElrath, M. J. (1995) · Seminars in Cancer Biology · doi:10.1016/1044-579x(95)90007-1 · Cited by 102
Traquina, P., Morandi, M., Contorni, M., & Nest, G. V. (1996) · The Journal of Infectious Diseases · doi:10.1093/infdis/174.6.1168 · Cited by 100
Butler, N. R., Voyce, M. A., Burland, W. L., & Hilton, M. L. (1969) · BMJ · doi:10.1136/bmj.1.5645.663 · Cited by 96
The Mucosal Adjuvant Activities of ADP-Ribosylating Bacterial Enterotoxins
Snider, D. P. (2017) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.v37.i2-6.150 · Cited by 94
Shalaby, W. S. W. (1995) · Clinical Immunology and Immunopathology · doi:10.1006/clin.1995.1019 · Cited by 90
The Mucosal Adjuvant Activities of ADP-Ribosylating Bacterial Enterotoxins
Snider, D. P. (1995) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.v15.i3-4.70 · Cited by 87
Alpar, H. O., Field, W. N., Hyde, R., & Lewis, D. (1989) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1989.tb06429.x · Cited by 81
Eosinophil Response to Alum Adjuvants: Involvement of T Cells in Non-Antigen-Dependent Mechanisms
Walls, R. S. (1977) · Experimental Biology and Medicine · doi:10.3181/00379727-156-39951 · Cited by 75
Vogel, F. R. (1998) · PubMed · Cited by 60
[6] Use of liposomes as biodegradable and harmless adjuvants
van Rooijen, N., & van Nieuwmegen, R. (1983) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(83)93036-7 · Cited by 52
Immunostimulatory DNA: A clear and present danger
Pisetsky, D. S. (1997) · Nature Medicine · doi:10.1038/nm0897-829 · Cited by 50
Vaccine Adjuvants Based on Gamma Inulin
Cooper, P. D. (1995) · Pharmaceutical biotechnology · doi:10.1007/978-1-4615-1823-5_24 · Cited by 48
Freestone, D. S., Hamilton-Smith, S., Schild, G. C., Buckland, R., Chinn, S., & Tyrrell, D. A. J. (1972) · Journal of Hygiene · doi:10.1017/s0022172400063117 · Cited by 48
Special Section:Future Trendsin Vaccination: Advances in cancer vaccine development
Herlyn, D., & Birebent, B. (1999) · Annals of Medicine · doi:10.3109/07853899909019264 · Cited by 46
Comparison between multilamellar and unilamellar liposomes in enhancing antibody formation.
Shek, P. N., Yung, B. Y. K., & Stanaćev, N. Ž. (1983) · PubMed · Cited by 45
Effectiveness of liposomes as adjuvants of orally and nasally administered tetanus toxoid
Alpar, H. O., Bowen, J. C., & Brown, M. R. (1992) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(92)90332-v · Cited by 43
Adjuvant effect of Ubenimex on a DNA vaccine for HIV-1
Sasaki, S., Fukushima, J., Hamajima, K., Ishii, N., Tsuji, T., Xin, K.-Q., Mohri, H., & Okuda, K. (1998) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.1998.00466.x · Cited by 43
Edelman, R., & Tacket, C. O. (1990) · International Reviews of Immunology · doi:10.3109/08830189009061764 · Cited by 39
The importance of mucosal immunology to problems in human reproduction
Anderson, D. J. (1996) · Journal of Reproductive Immunology · doi:10.1016/0165-0378(96)00979-5 · Cited by 29
Jones, G. L., Spencer, L., Lord, R. J., Mollard, R., Pye, D., & Saul, A. J. (1990) · Immunology Letters · doi:10.1016/0165-2478(90)90008-e · Cited by 28
Adjuvants and delivery systems for viral vaccines--mechanisms and potential.
Jennings, R., Simms, J. R., & Heath, A. W. (1998) · PubMed · Cited by 21
Physiological Effects of Mannans, Galactomannans, and Glucomannans
Davis, S., & LEWIS, B. A. (1975) · ACS symposium series · doi:10.1021/bk-1975-0015.ch019 · Cited by 14
Mekalanos, J. J. (1992) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-3410-5_6 · Cited by 13
Delivery systems for non-parenteral vaccines
Po, A. L. W., Rogers, E., Shepphard, M., & Scott, E. M. (1995) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(95)00097-q · Cited by 12
Cited by
Immunological properties of engineered nanomaterials
Dobrovolskaia, M. A., & McNeil, S. E. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.223 · Cited by 1,823
The Vaccine Adjuvant Monophosphoryl Lipid A as a TRIF-Biased Agonist of TLR4
Mata-Haro, V., Cekic, C., Martin, M., Chilton, P. M., Casella, C. R., & Mitchell, T. C. (2007) · Science · doi:10.1126/science.1138963 · Cited by 896
Peptide Vaccine: Progress and Challenges
Li, W., Joshi, M., Singhania, S., Ramsey, K., & Murthy, A. (2014) · Vaccines · doi:10.3390/vaccines2030515 · Cited by 679
Peptide-based synthetic vaccines
Skwarczynski, M., & Toth, I. (2016) · Chemical Science · doi:10.1039/c5sc03892h · Cited by 596
Oyewumi, M. O., Kumar, A., & Cui, Z. (2010) · Expert Review of Vaccines · doi:10.1586/erv.10.89 · Cited by 547
Metadata
- Authors
- Petrovsky, N., & Aguilar, J. C.
- Venue
- Immunology & Cell Biology
- Publisher
- Wiley
- Published
- 2004-09-28
- Volume
- 82
- Issue
- 5
- Pages
- 488-496
- ISSN
- 0004-945X (ISSN-L)
- 0818-9641
- 1440-1711
- OpenAlex
- W2052817467
- Cited by
- 1,005
- References
- 66
- FWCI
- 6.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.